What is the recommended pharmacological management of agitation in patients with dementia?

Pharmacological Management of Agitation in Dementia

Direct Recommendation

Start with SSRIs (citalopram 10 mg/day or sertraline 25-50 mg/day) as first-line pharmacological treatment for chronic agitation in dementia, reserving antipsychotics only for severe, dangerous agitation when behavioral interventions have failed and there is imminent risk of harm to self or others. 1

---

Treatment Algorithm

Step 1: Non-Pharmacological Interventions (Mandatory First-Line)

Before any medication is considered, you must systematically address reversible causes and implement behavioral strategies: 1

• Identify and treat medical precipitants: pain (major contributor in non-verbal patients), urinary tract infections, constipation, dehydration, pneumonia, hypoxia, and medication side effects (especially anticholinergic agents) 1
• Environmental modifications: adequate lighting, reduced noise, structured daily routines with predictable schedules for meals and bedtime, removal of hazardous items, installation of handrails 1, 2
• Communication strategies: calm tones, simple one-step commands, gentle touch for reassurance, allowing adequate time for processing information 1
• Behavioral techniques: use the "three R's" (repeat, reassure, redirect), distraction strategies, ABC charting to identify specific triggers 1, 2
• Document these interventions as attempted and insufficient before proceeding to pharmacological treatment 1, 3

Step 2: First-Line Pharmacological Treatment (Chronic Agitation)

When non-pharmacological interventions fail after adequate trial (24-48 hours to several weeks depending on severity), initiate SSRIs: 1

Preferred SSRI options:

• Citalopram: Start 10 mg/day, maximum 40 mg/day (well-tolerated, though some patients experience nausea and sleep disturbances; monitor QT interval) 1, 4
• Sertraline: Start 25-50 mg/day, maximum 200 mg/day (well-tolerated with less effect on metabolism of other medications) 1

Evidence supporting SSRIs:

• SSRIs significantly reduce overall neuropsychiatric symptoms, agitation, and depression in patients with dementia 1, 3
• Assess response using quantitative measures (Cohen-Mansfield Agitation Inventory or NPI-Q) at baseline and after 4 weeks 1
• If no clinically significant response after 4 weeks at adequate dose, taper and withdraw the medication 1
• Even with positive response, periodically reassess need for continued medication 1

Step 3: Alternative Pharmacological Options (If SSRIs Fail or Not Tolerated)

Trazodone: Start 25 mg/day, maximum 200-400 mg/day in divided doses 1

• Use with caution in patients with premature ventricular contractions due to risk of orthostatic hypotension and falls (30% falls risk in real-world studies) 1
• Preferred over benzodiazepines, which cause tolerance, addiction, cognitive impairment, and paradoxical agitation in 10% of elderly patients 1

Divalproex sodium: Start 125 mg twice daily, titrate to therapeutic blood level (for severe agitation without psychotic features) 1

• Monitor liver enzymes and coagulation parameters 1

Step 4: Antipsychotics (Reserved for Severe, Dangerous Agitation Only)

Antipsychotics should ONLY be used when: 1, 3

• Patient is severely agitated or distressed
• Threatening substantial harm to self or others
• Behavioral interventions have been thoroughly attempted and documented as insufficient
• Emergency situations with imminent risk of harm

Critical safety discussion required before initiating: 1

• Discuss increased mortality risk (1.6-1.7 times higher than placebo) with patient (if feasible) and surrogate decision-makers
• Explain cardiovascular effects, cerebrovascular adverse reactions, falls risk, QT prolongation, dysrhythmias, sudden death, hypotension, pneumonia, and metabolic effects
• Document expected benefits and treatment goals

Antipsychotic options (in order of preference):

For acute severe agitation:

• Haloperidol: 0.5-1 mg orally or subcutaneously, maximum 5 mg daily in elderly patients 1
• Use lowest effective dose for shortest possible duration with daily in-person reassessment 1

For severe agitation with psychotic features:

• Risperidone: Start 0.25 mg at bedtime, maximum 2-3 mg/day in divided doses (extrapyramidal symptoms at ≥2 mg/day) 1
• Quetiapine: Start 12.5 mg twice daily, maximum 200 mg twice daily (more sedating, risk of transient orthostasis) 1, 4
• Olanzapine: Start 2.5 mg at bedtime, maximum 10 mg/day in divided doses (less effective in patients >75 years) 1

Newer option:

• Brexiprazole: Only after non-pharmacological interventions exhausted, for severe dangerous symptoms 2

Critical antipsychotic caveats: 1, 3

• Benefits are at best small in clinical trials (standardized mean difference of -0.21)
• Patients over 75 years respond less well to antipsychotics, particularly olanzapine
• Approximately 47% of patients continue receiving antipsychotics after discharge without clear indication—avoid inadvertent chronic use
• Review need at every visit and taper if no longer indicated
• Monitor for extrapyramidal symptoms, falls, metabolic changes, QT prolongation, and cognitive worsening

---

What NOT to Use

Avoid these medications: 1

• Benzodiazepines: Do not use as first-line for agitated delirium (except alcohol/benzodiazepine withdrawal); increase delirium incidence and duration, cause paradoxical agitation in ~10% of elderly patients 1
• Typical antipsychotics (haloperidol, fluphenazine, thiothixene) as first-line therapy: 50% risk of tardive dyskinesia after 2 years of continuous use in elderly patients 1
• Cholinesterase inhibitors: Do not newly prescribe to prevent or treat delirium or agitation; associated with increased mortality 1
• Anticholinergic medications (e.g., diphenhydramine): Worsen agitation in dementia, not guideline-recommended 1

---

Monitoring and Reassessment Protocol

For all pharmacological treatments: 1, 2

• Use quantitative measures (Cohen-Mansfield Agitation Inventory or NPI-Q) at baseline and follow-up
• Evaluate response within 4 weeks (30 days) of initiating treatment
• For antipsychotics: daily in-person examination to evaluate ongoing need
• Monitor for side effects: extrapyramidal symptoms, falls, metabolic changes, QT prolongation, cognitive worsening, orthostatic hypotension
• If no clinically significant response after 4 weeks at adequate dose, taper and withdraw
• Consider tapering after 9 months to reassess necessity even with positive response
• Never continue antipsychotics indefinitely—review need at every visit

---

Common Pitfalls to Avoid

• Do not use antipsychotics for mild agitation—reserve for severe, dangerous symptoms only 1
• Do not skip non-pharmacological interventions unless in emergency with imminent harm 1
• Do not continue antipsychotics after discharge without clear ongoing indication—47% inadvertent chronic use rate 1
• Do not use benzodiazepines routinely—high risk of paradoxical agitation and cognitive worsening in elderly 1
• Do not forget to reassess pain—major contributor to behavioral disturbances in non-verbal patients 1
• Do not use typical antipsychotics as first-line—unacceptably high tardive dyskinesia risk 1